This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Vifor Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	6.9yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Vifor Pharma no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Alexandros Sigalas	Acting CFO & Head of IT & Administration	6.9yrs	sin datos	sin datos
Frederic Zwahlen	Head of Technical Operations	less than a year	sin datos	sin datos
Julien Vignot	Head of Investor Relations & Treasury	5.9yrs	sin datos	sin datos
Oliver Kronenberg	Group General Counsel	8.9yrs	sin datos	sin datos
Nathalie Ponnier	Global Head Corporate Communications	no data	sin datos	sin datos
Michael Puri	Chief Human Resources Officer	7.6yrs	sin datos	0.014% CHF 1.5m
Christoph Springer	Chief Strategy Officer	6.9yrs	sin datos	0.052% CHF 5.6m
Thomas Kaspar	Head of Global Quality Management	11.9yrs	sin datos	sin datos
Thierry Teil	Head of Global Medical Affairs	6.9yrs	sin datos	sin datos
Carolina Ponchione	Head of Executive Search & Employer Branding	4.9yrs	sin datos	sin datos
Barbara Angehrn	Chief Business Officer	4.1yrs	sin datos	0.0027% CHF 290.0k
Antonio Jordao	Regional Head of Southern Europe	no data	sin datos	sin datos

6.9yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: GNHA.Y's management team is seasoned and experienced (6.9 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jacques Theurillat	Independent Chairman of the Board	4.6yrs	CHF1.20m	0.0066% CHF 714.8k
Asa Riisberg	Independent Director	1.6yrs	CHF133.00k	sin datos
Etienne Jornod	Honorary Chairman	2.6yrs	CHF3.33m	sin datos
Alexandre Lebeaut	Independent Director	1.6yrs	CHF117.00k	sin datos
Michel Burnier	Independent Director	12.9yrs	CHF231.00k	0.017% CHF 1.8m
Romeo Cerutti	Independent Vice Chairman & Lead Independent Director	7.9yrs	CHF326.00k	0.015% CHF 1.6m
Kim Stratton	Independent Director	3.6yrs	CHF211.00k	0.0019% CHF 200.5k
Susan Mahony	Independent Director	3.6yrs	CHF260.00k	0.0022% CHF 236.1k

3.6yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: GNHA.Y's board of directors are considered experienced (3.6 years average tenure).

This company listing is no longer active

Vifor Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Announces Board Changes

Recent updates

Cancellation of Remaining Publicly Held Registered Shares of Vifor Pharma

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial

Vifor Pharma AG(SWX:VIFN) dropped from Swiss Performance Index (Price Return)

CSL Plans to Pursue an Application to SIX Exchange Regulation for the Delisting of the Vifor Pharma Shares

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®

Vifor Pharma and American Regent Announce Settlement Agreements with Mylan Laboratories Ltd., and Sandoz, Inc., of Injectafer Patent Litigation

Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing Business of Vifor Pharma Group.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Pharma AG Announces Enrolmenet of First Patient in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Vifor Says Regularly in Talks with Other Market Participants After Reports

Vifor Pharma AG (SWX:VIFN) entered into a definitive agreement to acquire Sanifit Therapeutics S.A. from group of investor for €375 million.

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Vifor Pharma to Revise DIAMOND Study

Vifor Pharma AG Approves Dividend, Payable from 12 May 2021

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Vifor Pharma AG Provides Phase-II Clinical Trial of VIT-2763 in Non-Transfusion-Dependent Beta-Thalassemia Is Expected to Be Completed in the Second Half of 2021

Vifor Pharma Announces Board Changes

Vifor Pharma Presents the Full Results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Optimus Holding Ltd. completed the acquisition of OM Pharma SA from Vifor Pharma AG (SWX:VIFN).

Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad